AU5965296A - Recombinant polypeptide cytotoxins for cancer treatment - Google Patents

Recombinant polypeptide cytotoxins for cancer treatment

Info

Publication number
AU5965296A
AU5965296A AU59652/96A AU5965296A AU5965296A AU 5965296 A AU5965296 A AU 5965296A AU 59652/96 A AU59652/96 A AU 59652/96A AU 5965296 A AU5965296 A AU 5965296A AU 5965296 A AU5965296 A AU 5965296A
Authority
AU
Australia
Prior art keywords
cancer treatment
recombinant polypeptide
polypeptide cytotoxins
cytotoxins
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59652/96A
Inventor
John P. Perentesis
Fatih M. Uckun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Publication of AU5965296A publication Critical patent/AU5965296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU59652/96A 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment Abandoned AU5965296A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45526395A 1995-05-31 1995-05-31
US455263 1995-05-31
PCT/US1996/008313 WO1996038571A2 (en) 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment

Publications (1)

Publication Number Publication Date
AU5965296A true AU5965296A (en) 1996-12-18

Family

ID=23808103

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59652/96A Abandoned AU5965296A (en) 1995-05-31 1996-05-31 Recombinant polypeptide cytotoxins for cancer treatment

Country Status (2)

Country Link
AU (1) AU5965296A (en)
WO (1) WO1996038571A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
DE19735105A1 (en) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg New fusion protein
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
CN100497387C (en) * 2001-05-25 2009-06-10 宾西法尼亚大学托管人 Chimeric proteins for cell targeting and apoptosis induction and methods of using same
WO2003087307A2 (en) * 2002-04-10 2003-10-23 Zymogenetics, Inc. Use of interleukin-19 to treat cervical cancer
PT3207941T (en) 2006-09-07 2020-04-02 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DK0610286T3 (en) * 1991-09-30 2000-07-17 Us Health Recombinant immunotoxins
WO1993025228A1 (en) * 1992-06-15 1993-12-23 Whittier Institute For Diabetes And Endocrinology Cytotoxins specific for gm-csf receptor-bearing cells
AU3582995A (en) * 1994-08-22 1996-03-14 Regents Of The University Of Minnesota Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer

Also Published As

Publication number Publication date
WO1996038571A2 (en) 1996-12-05
WO1996038571A3 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
AU5801296A (en) Crosslinkable polypeptide compositions
AU688210B2 (en) Recombinant obese (Ob) proteins
AU6916296A (en) Recombinant anti-cd4 antibodies for human therapy
AU6255096A (en) Pegylated modified proteins
AU5283793A (en) Recombinant specific binding protein
AU7203496A (en) Novel peptides
AU4230896A (en) Cancer inhibitory peptides
AU4544396A (en) Cells for the production of recombinant adenoviruses
AU4514193A (en) Bone formation-inducing protein
AU6844696A (en) Recombinant clone selection system
AU5289596A (en) Peptide suppressing ixbalpha phosphorylation
AU4427296A (en) Novel peptide
AU4394396A (en) Modified peptides
AU2131195A (en) Prophenins - antibiotic peptides
AU7166896A (en) Cancer treatment
AU5965296A (en) Recombinant polypeptide cytotoxins for cancer treatment
AU5021796A (en) Recombinant human anti-lewis b antibodies
AU4271793A (en) Novel polypeptide
AU5550296A (en) Conotoxin peptides
AU5648196A (en) Modified polypeptides for enhanced immunogenicity
AU7520396A (en) Abl-interactor protein
AU7059296A (en) NK-1 receptor antagonists for the treatment of cancer
AU5284296A (en) Immune-evading proteins
AU4582597A (en) Therapeutic proteins
AUPM489194A0 (en) Peptides